The IL-17 signaling pathway is targeted by four drugs that have been approved for adults with moderate to severe psoriasis: Secukinumab (Cosentyx®) in 2015, Ixekizumab (Taltz®) in 2016, Brodalumab (Siliq® in the USA, kyntheum® in EU) in 2017 and Bimekizumab (Bimzelx®) in 2023. Here, IL17A is linked to psoriasis.